Prof Milton Packer (Baylor University Medical Center, Dallas, TX, US), chief investigator of the EMPEROR-Reduced trial joined Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss the results of the study.
The purpose of EMPEROR-Reduced was to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Recorded remotely from Hamilton and Dallas, 2020.
Recording Editor: Michael Knight
Editor: Mirjam Boros